Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.

Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...

Among 134 men undergoing radical prostatectomy, PSMA PET accurately identified pathological tumor stage in 45% of patients compared with 28% of patients with MRI (P=0.003), reported Adam Kinnaird, MD, ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT improves locoregional staging compared with MRI in patients undergoing surgery for intermediate and high-risk prostate cancer. PSMA ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Key opportunities in the PET Radiotracers market include expanding cancer and neurological diagnostic applications, ...